Indo Borax & Chemicals Ltd

Acquisition overview

• Target: Kronox Lab Sciences Limited; line of business and country of presence not disclosed.
• Size: turnover or assets not disclosed.
• Related party: not a related party transaction.
• Industry/sector: not disclosed.
• Purpose and rationale: not disclosed.
• Regulatory approvals: not disclosed.
• Timeline: completed September 29, 2026.
• Consideration: equity shares; price not disclosed.
• Stake acquired: 64.26% via 2,38,44,000 shares.
• Background: incorporation date, products, turnover not disclosed.

Indo Borax & Chemicals Ltd - Closure of Trading Window

Funding for Kronox acquisition

• Indo Borax availed ~₹225 crore funding on 23 September 2026 to finance acquisition of Kronox Lab Sciences.
• Funding is from a lending institution; lender identity not disclosed.
• Further disclosures will be made as required under SEBI LODR.

Meeting details

• Event type: Analyst / Investor Meet (Company Update).

Purpose

• Purpose: investor interaction related to company performance and outlook.

Participants

• Key participants: management roles; individual names not disclosed.

Borrowing limits approved

• Purpose: Special resolution to approve borrowing limits up to Rs 400 crore under Section 180(1)(c).
• Resolution type: Special.
• Outcome: Approved; passed by requisite majority.
• Voting results: In-favour 18,751,916 (98.05%); against 373,158 (1.95%).
• Material impact: debt headroom increased to Rs 400 crore.
• Result announced: 11 September 2026.

Financial Performance

• Q1 FY27 operating revenue Rs 70.36 crore, up 31.34% YoY.
• Q1 FY27 EBITDA Rs 19.8 crore; EBITDA margin 28.1%.
• Q1 FY27 net profit Rs 16.25 crore; PAT margin 22.3%.
• Q1 FY27 EPS Rs 5.07.
• Q1 growth driven by execution, capacity utilization, and higher realizations.
• Full-year FY27 guidance: revenue Rs 250-260 crore; EBITDA around 20%.

Operations & Strategy

• Kronox acquisition: 64.26% equity stake; Dahej capex pending environmental clearances.
• Kronox capex plan Rs 110 crore; funded from internal accruals and Kronox cash.
• DOT forward integration: target 1,500 tons this year; higher margins from integration.
• Boric acid capacity: nameplate 20,000 t; last year 15,917 t; target 18,000 t this year.
• Utilization target: 96%–98% of capacity this year.
• Inter-company transactions: Boric Acid sales only; other flows at arm's length.

Capital Expenditure & Projects

• Total capex planned ~Rs 50 crore over 2–3 years: Boron oxide ~Rs 20 crore; Boric acid ~Rs 20–25 crore; Zinc Borate included.
• Kronox Phase I capex: Rs 55–60 crore; funded by internal accruals; remaining via loans.
• Open offer funding: Rs 151 crore; term loan; promoter Rs 25 crore contingency.

Guidance & Outlook

• FY27 EBITDA guidance ~20%; quarter-to-quarter volatility expected.
• Cross-selling and geographic expansion through Kronox to boost margin and reach.

Q&A Highlights

• Funding plan for Kronox: internal accruals ~Rs 180–190 crore; open offer ~Rs 151 crore; debt financing.
• Group strategy: focus on integration; no immediate additional acquisitions planned; organic + bolt-on growth.
• Boric acid moat: ~50% market share; IP grade 7–8% of sales; growing via pharma/personal-care focus.
• Open offer process: SEBI holding period; execution in parallel; not waiting for full open offer.

Meeting Details

• No date, time, or format disclosed in the provided excerpt.

Business overview

• Diversified specialty chemicals company focused on boron-based products.
• Core products include boric acid and DOT, with domestic demand growth.
• Board-approved amalgamation of Indo Borax Infrastructure Pvt Ltd with Indo Borax & Chemicals.
• Acquisition of Kronox Lab Sciences to broaden exports and premiumise offerings.
• Downstream expansion and debottlenecking opportunities to capture incremental domestic demand.

Operational highlights

• Q1 FY27 consolidated revenue rose 31.34% YoY to Rs 70.36 Cr.
• Q1 FY27 EBITDA Rs 19.80 Cr; margin 28.14%.
• Q1 FY27 net profit Rs 16.25 Cr; EPS Rs 5.07.
• FY26 revenue Rs 215.45 Cr; PAT Rs 50.27 Cr; EBITDA margin 20.5%.
• FY26 PAT margin 21.8%.

Strategic actions & acquisitions

• Board approved amalgamation of Indoborax Infrastructure with Indo Borax & Chemicals.
• Acquisition of 64.26% equity in Kronox Lab Sciences for Rs 246.12 Cr.
• Open Offer for up to 95,70,000 Kronox shares (25.79% stake).
• Kronox FY26 revenue Rs 101 Cr; PAT Rs 28 Cr; 185+ products.

Capital structure & liquidity

• Open Offer for Kronox to acquire up to 25.79% stake.
• Share count 32,090,000; market cap ~Rs 1,632 Cr as of Aug 31, 2026.

Strategic priorities & outlook

• Leverage Aatmanirbhar Bharat and Make in India for growth.
• Pursue downstream expansion and debottlenecking to meet domestic demand.
• Kronox acquisition to strengthen margins and export reach.

Risks & governance

• Macro demand volatility and industry cyclicality pose risks.
• Integration of Kronox and realization of synergies may affect margins.
• Management emphasizes disciplined execution and governance post-acquisitions.

Governance & leadership

• MD & CEO Suresh Kalra comments on strong quarterly performance.
• Board approvals for amalgamation and Kronox acquisition; open offer planned.

Rating Action

• Bank loan facilities placed on Rating Watch with Negative Implications by Ind-Ra.
• Long-term rating remains IND BBB+ with Rating Watch; short-term remains IND A2+ with Rating Watch.

Instruments & Ratings

• Instrument: Bank loan facilities; Revised rating under Rating Watch with Negative Implications.

Rationale & Key Drivers

• Acquisition of Kronox Lab Science promoter stake triggers watch.
• Open offer for up to 9,570,000 KLSL shares; approvals pending.
• Promoter debt financing around INR 2,250 mn; sanction pending.
• Completion and regulatory clearances will determine rating outcome.
• IBCL had no debt at FYE26; liquidity remains adequate.
• 100% promoter pledge remains key monitorable.
• FY26 revenue ₹2,154.5 mn; EBITDA ₹441.6 mn; margin 20.5%.
• 1QFY27 revenue ₹703.6 mn; EBITDA ₹198.1 mn.
• Capex ₹900 mn planned FY27-28; funded internally.
• Dividend ₹40 per share FY26; promoter-driven debt repayment planned.

Liquidity & Monitorables

• Liquidity cushion ₹2,638 mn at FYE26; no standalone debt.
• Promoter-level NCDs ₹2,550 mn; bullet repayment due FY31.
• Open offer completion and financing terms will influence post-transaction liquidity.
• Dividend payout and capex funded via internal accruals.

Rating Change & Next Steps

• Rating watch indicates potential affirmation or downgrade on resolution.
• Resolution contingent on acquisition completion and final debt terms.